evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 7 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Cannabidiol vs AMISULPRIDE

Cannabis use · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabidiol vs AMISULPRIDE

Mental state: PANSS total (high = bad) ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabidiol vs AMISULPRIDE

Global state: relapse ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabidiol vs AMISULPRIDE

General functioning ‐ no clinically important change in general functioning · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabidiol vs AMISULPRIDE

Adverse effects: measured adverse events ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabidiol vs AMISULPRIDE

Leaving the study early ‐ medium term ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabidiol vs AMISULPRIDE

Satisfaction with treatment ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review